Outlook Therapeutics, Inc.于2010年1月5日在新泽西州注册成立。该公司是一家生物制药公司，在欧盟或欧盟、英国或英国率先获得ONS-5010/LYTENAVA（贝伐珠单抗-gamma）眼科制剂上市许可，用于治疗湿性年龄相关性黄斑变性，或湿性AMD。该公司正在开发ONS-5010/LYTENAVA，作为玻璃体内注射液给药，用于治疗湿性AMD和视网膜疾病。
董事
名称
职位
C. Russell Trenary III
President, Chief Executive Officer and Director
Ralph H. Thurman
Executive Chairman of the Board, Director
Lawrence A. Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
Andong Huang
Director
Faisal G. Sukhtian
Director
Gerd Auffarth
Director
Julia A. Haller
Director
Julian Gangolli
Director
Kurt J. Hilzinger
Director
Yezan Haddadin
Director
股东
名称
职位
C. Russell Trenary III
President, Chief Executive Officer and Director
Lawrence A. Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director